A Phase 3 Evaluation of Daclatasvir in Combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with Chronic Hepatitis C Genotype 1b who are Treatment Naïve or Prior Relapsers to Alfa/RBV Therapy (The STRUCTURE Study)
Phase of Trial: Phase III
Latest Information Update: 24 May 2016
At a glance
- Drugs Daclatasvir (Primary) ; Peginterferon lambda-1a (Primary) ; Peginterferon alfa-2a; Ribavirin; Telaprevir
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms STRUCTURE
- Sponsors Bristol-Myers Squibb
- 07 Jun 2017 Biomarkers information updated
- 09 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 May 2014 Planned primary completion date changed from 1 Apr 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.